Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. on April 17, 2018. The filing discloses preliminary financial results as of March 31, 2018, referenced from a preliminary prospectus supplement filed on the same date. The company is identified as an emerging growth company.
Key Financial Metrics
Based on the company's current estimates as of March 31, 2018:
- Cash, Cash Equivalents, and Investments: Approximately $43.5 million.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: Specific debt figures are not disclosed; liquidity is represented by the cash position noted above.
Material Changes and Comparisons
The filing text does not provide a clear value for material changes versus the prior comparable period. The report focuses solely on the preliminary cash position as of the quarter-end date.
Guidance, Outlook, and Risks
Management Commentary and Status of Data: The financial data included is preliminary and subject to the company's financial closing procedures and final adjustments. The data has been prepared by management but has not been audited, reviewed, compiled, or subjected to agreed-upon procedures by PricewaterhouseCoopers LLP. Consequently, no assurance is expressed regarding the accuracy of these figures.
Legal Disclaimers: The information in Item 2.02 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. It shall not be incorporated by reference into other SEC filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Verify the final audited financial statements for the period ended March 31, 2018, once filed, as the $43.5 million cash figure is preliminary.
- Confirm the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.
- Review the preliminary prospectus supplement filed on April 17, 2018, for additional context on the financial condition.
- Note that PricewaterhouseCoopers LLP has not provided assurance on the data presented in this 8-K.